Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 1:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Steatohepatitis Clear all
Completed No phase listed Observational

Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition

NCT05011370
View directory record Official record
Conditions
Intestinal Failure-associated Liver Disease
Interventions
Not listed
Lead sponsor
Protara Therapeutics
Industry
Eligibility
12 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Kissimmee, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Jul 21, 2026, 1:54 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD

NCT03763877
View directory record Official record
Conditions
Nonalcoholic Fatty Liver
Interventions
PXL770, Placebo Oral Capsule
Drug
Lead sponsor
Poxel SA
Industry
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
15
States / cities
Los Angeles, California • Gainesville, Florida • Ocoee, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Jul 21, 2026, 1:54 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis

NCT04175392
View directory record Official record
Conditions
Fatty Liver Disease, Fibrosis, Liver, Cirrhosis, Liver, Steatohepatitis, Nonalcoholic
Interventions
Align Probiotic Supplement Capsule, Placebos
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Jul 21, 2026, 1:54 PM EDT
Completed Phase 2 Interventional Results available

The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)

NCT01265498
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Interventions
obeticholic acid, placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
9
States / cities
San Diego, California • San Francisco, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Jul 21, 2026, 1:54 PM EDT
Recruiting Phase 2 Interventional

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07288138
View directory record Official record
Conditions
Metabolic Dysfunction-associated Steatohepatitis
Interventions
Placebo, ECC4703, ECC0509
Drug
Lead sponsor
Eccogene
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
62
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 21, 2026, 1:54 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of Icosabutate in Fatty Liver Disease

NCT04052516
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis (NASH)
Interventions
Icosabutate, Placebo
Drug
Lead sponsor
NorthSea Therapeutics B.V.
Industry
Eligibility
18 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
38
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Jul 21, 2026, 1:54 PM EDT
Not listed No phase listed Observational

Validation Study of the Velacur System in Comparison to MRE & MRI-PDFF in Patients With (Suspected) Liver Disease

NCT05908006
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
Velacur
Device
Lead sponsor
GI Alliance
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Flowood, Mississippi • Webster, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Jul 21, 2026, 1:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Liver in the World Trade Center Health Program General Responder Cohort and Controls

NCT03858920
View directory record Official record
Conditions
Steatosis of Liver, NASH - Nonalcoholic Steatohepatitis
Interventions
Fibroscan of Liver, Low-dose non-contrast CT
Device · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years to 80 Years
Enrollment
340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Jul 21, 2026, 1:54 PM EDT
Recruiting Phase 2 Interventional

A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

NCT07325526
View directory record Official record
Conditions
Liver Cirrhosis
Interventions
BI 3802876, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
26
States / cities
Chandler, Arizona • Coronado, California • La Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 21, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose

NCT02571192
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
SHP626, 5.95 μCi RAD
Drug · Radiation
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Jul 21, 2026, 1:54 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

NCT05809934
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
AZD2693, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
37
States / cities
Chandler, Arizona • Peoria, Arizona • Surprise, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Jul 21, 2026, 1:54 PM EDT
Completed Phase 2 Interventional Results available

A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

NCT03776175
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease (NAFLD)
Interventions
PF-05221304 Monotherapy, PF-06865571 Monotherapy, Placebo, PF-05221304 and PF-06865571 Combination
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
29
States / cities
Bakersfield, California • Beverly Hills, California • Chula Vista, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Jul 21, 2026, 1:54 PM EDT
Terminated Phase 2 Interventional Results available

Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US

NCT05211284
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Saroglitazar Magnesium 4 mg, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Jul 21, 2026, 1:54 PM EDT
Recruiting Phase 3 Interventional

Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)

NCT05935826
View directory record Official record
Conditions
Hepatic Steatosis, NAFLD, Adolescent Obesity
Interventions
Essential Amino Acid Supplement by Amino Co, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
13 Years to 18 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Jul 21, 2026, 1:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER

NCT04165343
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Interventions
Positron Emission Tomography (PET) on EXPLORER, Magnetic Resonance Imaging, Echocardiogram and Electrocardiogram, Blood test
Radiation · Diagnostic Test
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Jul 21, 2026, 1:54 PM EDT
Completed Not applicable Interventional

Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease

NCT01327443
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
Weight loss, Exercise
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Jul 21, 2026, 1:54 PM EDT
Recruiting No phase listed Observational

Accurate Point of Care Liver Disease Diagnostics (Phase 2)

NCT07518784
View directory record Official record
Conditions
MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), NAFLD, NAFLD (Nonalcoholic Fatty Liver Disease)
Interventions
LiverScope® exam, MR exam, Blood draw, Body measurements, Questionnaire
Diagnostic Test · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 21, 2026, 1:54 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH

NCT00267670
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Liver Diseases
Interventions
Pentoxifylline, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Jul 21, 2026, 1:54 PM EDT
Active, not recruiting No phase listed Observational

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes

NCT04595474
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fibrosis, Liver, Type 1 Diabetes, Cirrhosis, Liver
Interventions
Transient Elastography
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 21, 2026, 1:54 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk

NCT01104220
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Metabolic Syndrome, Metabolically Abnormal Obesity, Metabolically Normal Obesity, Obesity
Interventions
Weight loss
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 90 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Jul 21, 2026, 1:54 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Blood Collection Biorepository for Liver Disease Research

NCT03025074
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis(NASH), Hepatitis C, Hepatitis B, Fibrosis, Cirrhosis, Fatty Liver, Obesity, Childhood, Bariatric Surgery Candidate
Interventions
Not listed
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
7 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2099
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Jul 21, 2026, 1:54 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rezdiffra Pregnancy and Lactation Registry

NCT07541469
View directory record Official record
Conditions
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Rezdiffra
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
West Conshohocken, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 21, 2026, 1:54 PM EDT
Completed Phase 2 Interventional Results available

Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)

NCT04198805
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Fatty Liver, Non-Alcoholic Steatohepatitis
Interventions
Vitamin E [(all-rac)-α-tocopheryl acetate], Omega-3 fatty acid (DHA EE), Omega-3 fatty acid (DHA EE) & Vitamin E [(all-rac)-α-tocopheryl acetate], Placebo
Dietary Supplement · Combination Product · Other
Lead sponsor
Naga P. Chalasani
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Chandler, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Jul 21, 2026, 1:54 PM EDT
Active, not recruiting Not applicable Interventional

Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD

NCT04861571
View directory record Official record
Conditions
NAFLD
Interventions
Dietary intervention with very low calorie diet (VLCD), Control Arm
Dietary Supplement · Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jul 21, 2026, 1:54 PM EDT